Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients
Sponsor: Pravat Mandal
Summary
The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.
Official title: Study For Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients
Key Details
Gender
All
Age Range
55 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
9
Start Date
2026-06
Completion Date
2027-02
Last Updated
2026-05-13
Healthy Volunteers
No
Conditions
Interventions
Gamma- Glutamylcysteine
400mg capsules once a day
Gamma- Glutamylcysteine
400mg capsules orally (two times) per day
Gamma- Glutamylcusteine
400mg capsules orally (three times) per day
Locations (1)
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania, United States